

**Information for Connecticut Prescribing Practitioners and Pharmacists Provided Pursuant to Connecticut Public Act No. 23-171 (Effective October 1, 2023)**

In accordance with Connecticut Public Act No. 23-171, TG Therapeutics, Inc. is disclosing to prescribing practitioners and pharmacists in Connecticut certain required “list price,” or wholesale acquisition cost (“WAC”), information for its marketed prescription drug, BRIUMVI. The information provided herein is accurate as of the effective date of this notice.

The price listed below is the WAC price for each NDC-11 of BRIUMVI, established and made available to the public by a third-party publisher. This WAC price represents TG Therapeutics’ published list price for each BRIUMVI NDC-11 sold to wholesalers before any prompt pay or other discounts, rebates, or reductions in price. The listed WAC price may differ significantly from the actual prices paid by customers and consumers for BRIUMVI. In addition, a product’s WAC price is typically not associated with per-dose pricing, and does not necessarily reflect the price per dosage, price per course of treatment, or the cost effectiveness of BRIUMVI.

Please refer to the BRIUMVI website [www.briumvi.com](http://www.briumvi.com) for additional information about the product, including its FDA-approved prescribing information.

<b>NDC-11</b>	<b>Drug Name and Description</b>	<b>WAC*</b>
73150-0150-06	BRIUMVI (ublituximab-xiiy) 150 mg/6 mL Vial	\$10,472.50

For more information on the price disclosure requirements, please contact the Connecticut State Board of Pharmacy at:

State Board of Pharmacy  
450 Columbus Blvd  
Hartford, CT 06103  
Ph. (860) 713-6070

Website: <https://portal.ct.gov/DCP/DrugControl-Division/Commission-of-Pharmacy/The-Commission-of-Pharmacy>

\* WAC price as of January 12, 2024.

BRIUMVI is a trademark of TG Therapeutics, Inc.

Last updated: January 12, 2024.